insights_auto
Why is BH3 down ၃.၃၇%?
Dive Deeperchevron_right
BH3:FRA
PTC Therapeutics, Inc.
၅၅.၀၀ €
arrow_downward
-၃.၃၇%(-၁.၉၂) 1D
အောက် ၁၃, GMT+၂ ၁၁:၄၆:၁၇ · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BH3...
Open
၅၄.၉၀ €
High
၅၅.၀၀ €
Low
၅၄.၉၀ €
Mkt. cap
၅၀၅.၀၂ ဋေ
Avg. vol.
၀.၀၀
Volume
၀.၀၀
52-wk high
၇၇.၀၂ €
52-wk low
၅၂.၅၀ €
No. of employees
၉၉၁
Open
၅၄.၉၀ €
High
၅၅.၀၀ €
Low
၅၄.၉၀ €
Mkt. cap
၅၀၅.၀၂ ဋေ
Avg. vol.
၀.၀၀
Volume
၀.၀၀
52-wk high
၇၇.၀၂ €
52-wk low
၅၂.၅၀ €
No. of employees
၉၉၁
News stories
From web sources and news partners
Investing.com
·
ပြီးခဲ့သည့် ၅ နာရီ
Ptc Therapeutics stock hits 52-week low at $61.20 By Investing.com
Investing.com
·
ပြီးခဲ့သည့် ၁၄ နာရီ
PTC Therapeutics director Glenn Steele sells $781,920 in shares
Investing.com Canada
·
ပြီးခဲ့သည့် ၂ ရက်
Form 144 PTC THERAPEUTICS For: 10 October By Investing.com
Profile
PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control mechanisms in orphan diseases.
In September 2009, PTC entered into an agreement with Roche for the development of orally bioavailable small molecules for central nervous system diseases. PTC acquired the Bio-e platform in 2019. Wikipedia
About PTC Therapeutics, Inc.
CEOMatthew B. Klein
Employees၉၉၁
Founded၁၉၉၈ ဇန် ၁
HeadquartersWarren, နယူးဂျာစီပြည်နယ်, ယူနိုက်တက်စတိတ်
Sector-
Websiteptcbio.com